Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NAT1 | P18440 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7612387 | 0.81 | PTGS2 (0.39) | PTGS2MEN1POLBKMT2ANAT1 | |
| SCHEMBL5377415 | 0.72 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL6844095 | 0.70 | MEN1 (0.39) | PTGS2MEN1POLBKMT2APTGS1 | |
| SCHEMBL6846588 | 0.70 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL6846585 | 0.69 | PTGS2 (0.44) | PTGS2PTGS1L3MBTL1 | |
| SCHEMBL6846488 | 0.67 | PTGS2 (0.36) | PTGS2KMT2APTGS1 | |
| SCHEMBL6838945 | 0.65 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL7617482 | 0.62 | PTGS1 (0.44) | PTGS2PTGS1 | |
| SCHEMBL2333956 | 0.62 | L3MBTL1 (0.59) | KMT2ACA1CA2L3MBTL1 | |
| SCHEMBL31195820 | 0.62 | L3MBTL1 (0.59) | KMT2ACA1CA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242637-A1 | Tyrosine kinase inhibitors | HARTMAN GEORGE D (US) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242637-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | PTGS2 983/4885MEN1 4406/4885POLB 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.